SCHEMBL6133028

SCHEMBL6133028

O=C1CNC(=O)C(Cc2cccc(NCc3ccccc3)c2)N1

nearest known ligand 0.44

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
GHSR Q92847 2/20 0.42
DDB1 Q16531 1/20 0.41
CRBN Q96SW2 1/20 0.41
ITGB3 P05106 2/20 0.41
ITGAV P06756 2/20 0.41
ITGB5 P18084 2/20 0.41
HDAC8 Q9BY41 2/20 0.40
FFAR1 O14842 1/20 0.40
HRH3 Q9Y5N1 2/20 0.39
HTR2C P28335 1/20 0.39
OPRM1 P35372 3/20 0.39
OPRD1 P41143 3/20 0.39
MAOA P21397 1/20 0.39
OPRK1 P41145 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1598687 0.81 HDAC8 (0.57) GHSRITGB3ITGAVHDAC8HRH3
SCHEMBL1673516 0.81 HDAC8 (0.57) GHSRITGB3ITGAVHDAC8HRH3
SCHEMBL7304234 0.81 HDAC8 (0.57) GHSRITGB3ITGAVHDAC8HRH3
SCHEMBL8135311 0.79 HDAC8 (0.54) GHSRITGB3ITGAVHDAC8HRH3
SCHEMBL12148795 0.79 HDAC8 (0.54) GHSRITGB3ITGAVHDAC8HRH3
SCHEMBL5559197 0.78 HRH3 (0.46) GHSRITGB3ITGAVHDAC8HRH3
SCHEMBL12809720 0.77 HRH3 (0.44) GHSRHRH3OPRM1OPRD1OPRK1
Acetic Acid SCHEMBL27525272 0.75 OPRM1 (0.51) GHSRITGB3ITGAVHDAC8HRH3
SCHEMBL6132977 0.74 BRD4 (0.46) HDAC8HRH3
SCHEMBL6132871 0.74 GHSR (0.43) GHSRDDB1CRBNITGB3ITGAV

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1255401-C Aroyl-piperazine derivatives, their preparation and their use as tachykinin antagonists FUJISAWA PHARMACEUTICAL CO (JP) 2006-05-10 CN disclosed
US-6924278-B2 Heterocyclic carboxy amines such as (2R)-1-[3,5-Bis(trifluoromethyl)benzoyl]-4-[4-((3S)-3-ethylmorpholino)-2-butynyl]-2-[(1H-indol-3-yl)methyl]piperazine, used as substance P and neurokinin antagonist for prophylaxis of diseases FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-08-02 US disclosed
US-20050027121-A1 Aroyl-piperazine derivatives, their preparation and their use as tachykinin antagonists FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-02-03 US disclosed
US-20030114668-A1 AROYL-PIPERAZINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-06-19 US disclosed
CN-1266431-A Aroyl-piperazine derivatives, their preparation and their use as tachykinin antagonists FUJISAWA PHARMACEUTICAL CO (JP) 2000-09-13 CN disclosed
EP-0993457-A1 AROYL-PIPERAZINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-04-19 EP disclosed
WO-1998057954-A1 AROYL-PIPERAZINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1998-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050027121-A1 Aroyl-piperazine derivatives, their preparation and their use as tachykinin antagonists TAC3, TACR1, SSTR5 GHSR 359/4885DDB1 4845/4885CRBN 2067/4885
US-20030114668-A1 AROYL-PIPERAZINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS TACR1, NPSR1, SSTR2 GHSR 230/4885DDB1 4730/4885CRBN 2589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.